Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
Conditions
Interventions
Tradipitant
Placebo
Locations
51
United States
Vanda Investigational Site
Hoover, Alabama, United States
Vanda Investigational Site
Tempe, Arizona, United States
Vanda Investigational Site
Encino, California, United States
Vanda Investigational Site
Fountain Valley, California, United States
Vanda Investigational Site
Laguna Hills, California, United States
Vanda Investigational Site
Lomita, California, United States
Start Date
October 21, 2019
Primary Completion Date
October 14, 2020
Completion Date
October 14, 2020
Last Updated
May 14, 2024
NCT07298395
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
Vanda Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions